Cholinesterase, Serum, with Dibucaine Inhibition
Order Name
PSEUDO/DI
Test Number: 3608550
Revision Date 12/12/2022
Test Number: 3608550
Revision Date 12/12/2022
| Test Name | Methodology | LOINC Code |
|---|---|---|
|
Cholinesterase Serum
|
Kinetic Spectrophotometric | 2098-2 |
|
Dibucaine Number % inhibition
|
39354-6 |
| SPECIMEN REQUIREMENTS | ||||
|---|---|---|---|---|
| Specimen | Specimen Volume (min) | Specimen Type | Specimen Container | Transport Environment |
| Preferred | 1 mL | Serum | Clot Activator SST | Room Temperature |
| Instructions | Specimen Type: Gel-Barrier Tube Specimen Stability: Ambient: Not Available, Refrigerated : Not Available, Frozen: Not Available |
|||
| GENERAL INFORMATION | |
|---|---|
| Testing Schedule | Fri |
| Expected TAT | 2-9 days |
| Clinical Use | The Pseudocholinesterase phenotype can be determined by analysis of Pseudocholinesterase and the percent inhibition by Dibucaine. Approximately 96% of the population has normal activity, approximately 4% will exhibit decreased activity that leads to prolonged paralysis following use of succinylcholine, and 1 in 3000 patients will exhibit severe , prolonged paralysis following anesthetic exposure. |
| Performing Labcorp Test Code | 302107 |
| Notes | Labcorp Test Code: 302107 |
| CPT Code(s) | 82480; 82638 |
| Lab Section | Reference Lab |